Which statement best describes the role of PCR-based sequencing in Blastocystis subtyping in clinical practice?

• A. It is routinely used in most clinics
• B. It is not used
• C. Remains research-level
• D. It is required for diagnosis

Answer: (C)

PCR-based sequencing to subtype Blastocystis is mostly a research activity. Sequencing the amplified Blastocystis DNA to assign subtypes (such as ST1, ST2, etc.) provides valuable information for epidemiology, transmission patterns, and population studies, but it does not currently change how patients are treated. There isn’t a consistent link between subtype and disease severity or response to therapy that would make subtype data essential for routine care. Because of this, most clinics do not perform subtyping as part of standard diagnostics. Subtyping is more commonly offered by reference or research laboratories when specific epidemiologic questions arise or when a study is investigating subtype distribution, outbreaks, or zoonotic transmission. For everyday clinical practice, the focus remains on detecting the presence of Blastocystis rather than determining its subtype, and subtyping is not required for diagnosis.